Loading

Maximizing value of intellectual property portfolios in cell and gene therapies to attract investors

11 Feb 2026
Theatre 1
Roundtable
  • Advantages and strategies for extending Loss of Exclusivity (LOE) beyond regulatory exclusivity
  • Preparing for investor IP diligence scrutiny
  • Knowing the patent landscape to proactively address freedom-to-operate inquiries
Chairperson
Bonnie Nannenga-Combs, Director - Sterne Kessler, Goldstein & Fox

Brought to you by

Sterne, Kessler, Goldstein & Fox